AZN vs IVVD

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

Invivyd exhibits critical financial weakness, highlighted by a Piotroski F-Score of 0/9, indicating a complete lack of fundamental improvement across all measured categories. While the company maintains a strong liquidity position with a Current Ratio of 7.24 and very low debt, it is suffering from extreme operational inefficiency with a profit margin of -98.25%. There is a stark disconnect between the analyst 'Strong Buy' consensus (Target $10.00) and the deterministic data, which shows consistent earnings misses and bearish insider activity.